Pantep Angchaisuksiri
A5038277854- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Platelet Disorders and Treatments
- Hemophilia Treatment and Research
- Blood Coagulation and Thrombosis Mechanisms
- COVID-19 Clinical Research Studies
- Cardiac Arrhythmias and Treatments
- Diagnosis and Treatment of Venous Diseases
- Hemoglobinopathies and Related Disorders
- COVID-19 and healthcare impacts
- Heparin-Induced Thrombocytopenia and Thrombosis
- Acute Ischemic Stroke Management
- Central Venous Catheters and Hemodialysis
- Blood groups and transfusion
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Acute Myeloid Leukemia Research
- Acute Myocardial Infarction Research
- Hemostasis and retained surgical items
- Iron Metabolism and Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Intramuscular injections and effects
- Blood properties and coagulation
Ramathibodi Hospital
2016-2025
Mahidol University
2016-2025
University of North Carolina at Chapel Hill
1996-2024
Ministry of Public Health
2022
Department of Disease Control
2022
University of Benin Teaching Hospital
2020
University of Calabar
2020
McMaster University
2019
KLE Society Hospital
2018
Sir Ganga Ram Hospital
2018
Background: Coronavirus disease 2019 (COVID-19)–related critical illness and acute are associated with a risk of venous thromboembolism (VTE). Objective: These evidence-based guidelines the American Society Hematology (ASH) intended to support patients, clinicians, other health care professionals in decisions about use anticoagulation for thromboprophylaxis patients COVID-19–related who do not have confirmed or suspected VTE. Methods: ASH formed multidisciplinary guideline panel applied...
Concizumab is an anti-tissue factor pathway inhibitor monoclonal antibody designed to achieve hemostasis in all hemophilia types, with subcutaneous administration. A previous trial of concizumab (explorer4) established proof concept patients or B inhibitors.We conducted the explorer7 assess safety and efficacy inhibitors. Patients were randomly assigned a 1:2 ratio receive no prophylaxis for at least 24 weeks (group 1) 32 2) nonrandomly (groups 3 4). After treatment pause due nonfatal...
Well-characterized genes that affect warfarin metabolism (cytochrome P450 (CYP) 2C9) and sensitivity (vitamin K epoxide reductase complex 1 (VKORC1)) explain one-third of the variability in therapeutic dose before international normalized ratio (INR) is measured. To determine genotypic relevance after INR becomes available, we derived clinical pharmacogenetic refinement algorithms on basis values (on day 4 or 5 therapy), factors, genotype. After adjusting for INR, CYP2C9 VKORC1 genotypes...
Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a target range of international normalised ratio (INR) 2.0–3.0 for stroke prevention in atrial fibrillation (AF). We analysed the time this therapeutic (TTR) VKA-treated patients with newly diagnosed AF ongoing, global, observational registry GARFIELD-AF. Taking TTR as measure quality patient management, we its relationship 1-year outcomes, including stroke/systemic embolism (SE), major...
Asian venous thromboembolism guidelines: updated recommendations
Coronavirus disease 2019 (COVID-19) is associated with significant hypercoagulability. However, despite prophylactic anticoagulation, critically ill patients this condition develop thromboses. This forum discusses the lungs as epicenter for hemostatic issues, puts forward a proposal staging COVID-19 coagulopathy based on available diagnostic markers, and suggest considering current future treatment options these different stages.
Management of venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE), varies worldwide. The Global Anticoagulant Registry in the FIELD - Venous Thromboembolism (GARFIELD-VTE) is a prospective, observational study 10,685 patients with objectively diagnosed VTE recruited from May 2014 to January 2017 at 417 sites 28 countries. All are followed for least 3 years. We describe baseline characteristics population their management within 30 days...
Abstract Background COVID-19–related acute illness is associated with an increased risk of venous thromboembolism (VTE). Objective These evidence-based guidelines the American Society Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about use anticoagulation for thromboprophylaxis patients COVID-19 who do not have confirmed or suspected VTE. Methods ASH formed a multidisciplinary guideline panel, including 3 patient...
Abstract Background: COVID-19–related acute illness is associated with an increased risk of venous thromboembolism (VTE). Objective: These evidence-based guidelines from the American Society Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in making decisions about use anticoagulation patients COVID-19. Methods: ASH formed a multidisciplinary guideline panel that included patient representatives applied strategies minimize potential bias...
Abstract Background: COVID-19–related critical illness is associated with an increased risk of venous thromboembolism (VTE). Objective: These evidence-based guidelines the American Society Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about use anticoagulation for patients COVID-19. Methods: ASH formed a multidisciplinary guideline panel, including 3 patient representatives, applied strategies minimize potential bias from...